Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia-Reference-Cited by-同舟云学术

Phase 1 clinical trial of adoptive immunotherapy using “off-the-shelf” activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia

Published:2017-10 Issue:10 Volume:19 Page:1225-1232
ISSN:1465-3249
Container-title:Cytotherapy
language:en
Short-container-title:Cytotherapy

Author:

Boyiadzis Michael,Agha Mounzer,Redner Robert L.,Sehgal Alison,Im Annie,Hou Jing-Zhou,Farah Rafic,Dorritie Kathleen A.,Raptis Anastasios,Lim Seah H.,Wang Hong,Lapteva Natalia,Mei Zhuyong,Butterfield Lisa H.,Rooney Cliona M.,Whiteside Theresa L.

Funder

Production Assistance for Cellular Therapies

National Heart, Lung, and Blood Institute

NantKwest, Inc

Publisher

Elsevier BV

Subject

Cancer Research,Transplantation,Cell Biology,Genetics(clinical),Oncology,Immunology,Immunology and Allergy

Reference27 articles.

1. Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens;Childs;Nat Rev Drug Discov,2015

2. Emerging insights into natural killer cells in human peripheral tissues;Bjorkstrom;Nat Rev Immunol,2016

3. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants;Ruggeri;Science,2002